ISPO

Published in Cancer Detection and Prevention 1993; 17(1).

Immature (precursor) myeloma cells may be target cells for treatment of human multiple myelomas

Kawano MD, M.M., Harada MD, H., Huang BS, N., Harada MD, Y., Sakai MD, A., Kuramoto MD, A.

Dept. of Int. Med., Res. Ins. Nucl. Med. Biol., Hiroshima Univ., 1-2-3 Kasumi, Minami-ku, Hiroshima 734, Japan.

Two-color phenotypic analysis with anti-CD38 antibody revealed that human myeloma cells consisted of morphologically immature CD38++VLA-5(lintegrin)- cells and mature CD38++VLA-5+ cells. VLA-5- myeloma cells sorted by a cell sorter had high proliferative activity and proliferative response to interleukin 6(IL-6), while VLA-5-+ myeloma cells showed almost no proliferation and no response to IL-6 but secreted higher amounts of Ig in vitro. Furthermore, only VLA-5- immature myeloma cells were detected in the peripheral blood of myeloma patients. In the aggravated patients, the increase in VLA-5- myeloma cells were found. Therefore, VLA-5- immature myeloma cells may be clonogenic and precursor cells.

Paper presented at the International Symposium on Genetic Factors in Predictive and Preventive Oncology; Nice, France; March 14-16, 1993; in the section on Prognostic Indicators.

http://www.cancerprev.org/Journal/Issues/17/1/5/1474